Omar Nadeem
Overview
Explore the profile of Omar Nadeem including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
442
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, et al.
Blood Adv
. 2025 Mar;
PMID: 40088469
No abstract available.
2.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Mar;
:JCO2500453.
PMID: 40053892
No abstract available.
3.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401730.
PMID: 39965175
Purpose: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety,...
4.
ODonnell E, Carroll J, Perry J, Padgett K, Harris B, Patel V, et al.
Blood Adv
. 2025 Feb;
PMID: 39903136
No abstract available.
5.
Nadeem O, Ghobrial I
Nat Rev Clin Oncol
. 2025 Jan;
22(3):159-160.
PMID: 39856237
No abstract available.
6.
Nadeem O, Aranha M, Redd R, Timonian M, Magidson S, Lightbody E, et al.
Nat Commun
. 2025 Jan;
16(1):358.
PMID: 39753553
Early therapeutic intervention in high-risk smoldering multiple myeloma (HR-SMM) has shown benefits, however, no studies have assessed whether biochemical progression or response depth predicts long-term outcomes. The single-arm I-PRISM phase...
7.
Vogl D, Atrash S, Holstein S, Nadeem O, Benson Jr D, Benson D, et al.
Blood
. 2024 Dec;
145(9):944-955.
PMID: 39630057
Interferon alfa has activity against multiple myeloma (MM). Modakafusp alfa is an immunocytokine comprising 2 attenuated interferon alfa-2b molecules and an anti-CD38 immunoglobulin G4 antibody, targeting delivery of interferon alfa...
8.
Yee A, Laubach J, Campagnaro E, Lipe B, Nadeem O, Friedman R, et al.
Blood Adv
. 2024 Dec;
9(5):1163-1170.
PMID: 39626297
Elotuzumab is a monoclonal antibody targeting signaling lymphocyte activation molecule F7 on plasma and natural killer cells, which enhances the activity of lenalidomide, pomalidomide, and bortezomib in multiple myeloma (MM)....
9.
Itzhaki Ben Zadok O, Simitsis P, Jacobson C, Nadeem O, Frigault M, Raje N, et al.
Circulation
. 2024 Nov;
150(22):1815-1817.
PMID: 39585929
No abstract available.
10.
Marinac C, Downey K, Perry J, Fisher-Longden B, Rebbeck T, Shah U, et al.
Blood Cancer J
. 2024 Oct;
14(1):185.
PMID: 39433741
No abstract available.